Clinical Trial Update: Evaluating the Efficacy and Safety of the Lower Dose of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation- KMM103 Study [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update outlines evaluation of a lower-dose conditioning regimen consisting of bortezomib with busulfan and melphalan in patients with multip…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BUSULFAN (Busulfan)
• Bortezomib (bortezomib)
• Melphalan (Melphalan)

Snippet

Sponsor: Yonsei University | Conditions: Multiple Myeloma Patients Who Candidate for Autologous Peripheral Blood Stem Cell Transplantation | Phase 1, Phase 2 | Status: UNKNOWN